Loading...

PODCAST

Project Oncology®

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in

science & medicine medicine

All Episodes

00:02:15

How ALK Vaccines Could Prolong TKI Response in mNSCLC

Project Oncology® ·

2026/10/05

Guest: Angel Qin, MD Checkpoint inhibitors have shown limited efficacy in ALK+ metastatic non-small cell lung cancer (mNSCLC), but could a different immunologic strategy complement targeted therapy? Dr. Angel Qin discusses the rationale for ALK vaccines and explains how harnessing an ALK-specific immune response may help extend the durability of ALK TKI therapy. She's a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School.

en

00:02:15

From Durability to Discovery: Advances in ALK+ mNSCLC...

Project Oncology® ·

2026/10/05

Guest: Angel Qin, MD The treatment landscape for ALK+ metastatic non-small cell lung cancer (mNSCLC) is continuing to evolve, with durable outcomes from frontline ALK inhibition and emerging therapies offering new possibilities across disease settings. Join Dr. Angel Qin, Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School, as she examines the evidence on current and emerging treatment options for this population.

en

00:02:30

How Novel Strategies Could Push ALK+ mNSCLC Care Forward

Project Oncology® ·

2026/10/05

Guest: Angel Qin, MD Even with increasingly effective targeted therapies for ALK+ metastatic non-small cell lung cancer (mNSCLC), unanswered questions remain, especially when a patient's disease progresses or treatment becomes difficult to tolerate. In this program, Dr. Angel Qin looks beyond current care strategies to consider where the field is headed, from overcoming resistance to investigating entirely different ways of extending disease control. Dr. Qin is a Clinical Associate

en

00:04:30

Exploring Sub-Ablative Radiation to Modulate Immunity...

Project Oncology® ·

2026/10/05

Guest: John Cho, MD, PhD, FRCPC Could lower doses of radiation help optimize immune response in mesothelioma? Dr. John Cho joins us to explain how tailoring radiation to a tumor’s inflammatory and immunogenic characteristics could help modulate antitumor immunity while reducing the potential for fibrosis and treatment-related toxicity. Dr. Cho is a radiation oncologist at the Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the

en

00:05:00

Investigating Unanswered Questions in ALK+ mNSCLC Care

Project Oncology® ·

2026/10/02

Guest: Alice T. Shaw, MD, PhD Despite major advances in targeted therapy for ALK+ metastatic non-small cell lung cancer (mNSCLC), challenges remain in achieving durable responses and preventing treatment resistance. Hear from Dr. Alice Shaw as she explores key unanswered questions and emerging research aimed at addressing gaps in care for these patients. Dr. Shaw is the Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard

en

00:04:30

Guiding mNSCLC Treatment After ALK-TKI Progression

Project Oncology® ·

2026/10/02

Guest: Alice T. Shaw, MD, PhD In metastatic non-small cell lung cancer (mNSCLC), resistance to ALK TKIs can differ depending on which therapies a patient has previously received, with important implications for next steps in treatment. Dr. Alice Shaw explains how treatment history and molecular testing at progression can help identify ALK-dependent and other actionable resistance mechanisms to help inform next-line therapy. She's the Chair of the Department of Medical Oncology at

en

00:02:45

Patterns of Progression and Resistance in ALK+ mNSCLC

Project Oncology® ·

2026/10/02

Guest: Alice T. Shaw, MD, PhD Despite advances in ALK inhibition, resistance remains an important challenge in metastatic ALK+ non-small cell lung cancer (NSCLC). Dr. Alice Shaw, Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, explores patterns of disease progression, emerging on- and off-target resistance mechanisms, and the potential role of combination approaches in overcoming resistance.

en

00:09:30

Comparing CAR T-Cell Therapies for R/R Multiple Myeloma

Project Oncology® ·

2026/09/28

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc As CAR T-cell therapy options expand for relapsed or refractory (R/R) multiple myeloma, comparative data may help clinicians weigh efficacy and safety when selecting treatment. One recent matching-adjusted indirect comparison of anitocabtagene autoleucel and ciltacabtagene autoleucel drew on data from the iMMAGINE-1 and CARTITUDE-1 trials to evaluate response and safety outcomes, including cytokine release

en

00:15:30

CAR T-Cell vs Bispecific Therapies for R/R Multiple...

Project Oncology® ·

2026/09/28

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc A recent analysis used matching-adjusted indirect comparisons to evaluate anitocabtagene autoleucel, teclistamab, and talquetamab for relapsed or refractory (R/R) multiple myeloma, drawing on data from the iMMAGINE-1, MajesTEC-1, and MonumenTAL-1 trials. The analysis compared efficacy and safety outcomes across these CAR T-cell and bispecific therapies, including overall response, depth of response, MRD

en

00:04:45

A Patient-First Approach to Smoking Cessation and...

Project Oncology® ·

2026/09/18

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM Even well-intentioned conversations about tobacco use can leave patients feeling judged and potentially less willing to engage in lung cancer screening, follow-up, or cessation support. Tune in as Dr. Lisa Carter-Bawa shares practical strategies for fostering more supportive, patient-centered conversations that reduce stigma and keep the door open to screening and continued care. In addition to being the Director of the Cancer

en

00:04:00

Tobacco-Related Stigma as a Barrier to Lung Cancer...

Project Oncology® ·

2026/09/18

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM For patients who smoke or have a history of smoking, seeking lung cancer screening can mean confronting more than the fear of a diagnosis; it can also mean anticipating blame and judgment. Dr. Lisa Carter-Bawa joins us to share how tobacco-related stigma and nihilism can discourage screening, honest conversations, and follow-up care. Learn how approaching patients with greater awareness and compassion can help create a more

en

00:02:45

Key Questions Shaping Chemotherapy-Free Treatment in...

Project Oncology® ·

2026/09/09

Guest: Jonathon B. Cohen, MD, MS As chemotherapy-free approaches for mantle cell lymphoma continue to evolve, important questions remain about how best to incorporate them into clinical practice. Here to help shed light on the key unknowns surrounding patient selection, treatment sequencing, and the potential implications of using targeted and immune therapies in the frontline setting is Dr. Jonathon Cohen. He’s a board-certified hematologist and medical oncologist at Emory Winship

en

00:03:15

A Look at WCLC 2026: Pivotal Trials and Emerging...

Project Oncology® ·

2026/09/04

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in

en

00:04:45

Resistance and Transformation in EGFR-Mutant Lung Cancer

Project Oncology® ·

2026/09/04

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed

en

00:02:30

Making the Most of WCLC 2026: A Guide for...

Project Oncology® ·

2026/09/04

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio

en

00:12:45

Applying Clinical Trial Data in mCSPC Care

Project Oncology® ·

2026/07/15

Host: Steve Jackson, PharmD Guest: Jahan Aghalar, MD Guest: Ulka Vaishampayan, MD With more treatment options than ever for metastatic castration-sensitive prostate cancer (mCSPC), applying clinical trial data in everyday practice has become increasingly complex. Understanding how differences in trial design, patient populations, and clinical endpoints influence treatment decisions is essential for delivering personalized care. Join Dr. Steve Jackson as he speaks with Drs

en

00:11:15

Personalizing Long-Term mCSPC Treatment Decisions

Project Oncology® ·

2026/07/15

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bilal Siddiqui, MD Long-term management of metastatic castration-sensitive prostate cancer (mCSPC) goes beyond selecting an effective therapy—it also requires careful consideration of tolerability, drug interactions, and treatment access. Balancing these factors can help clinicians personalize care while supporting adherence and quality of life over time. Joining Dr. Charles Turck to share practical strategies for navigating these

en

00:13:45

Evidence-Based Treatment Decisions in Metastatic...

Project Oncology® ·

2026/07/01

Host: Alexandria May, PharmD, BCPS Guest: Neil M. Iyengar, MD As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr

en

00:02:15

Building on Progress in ALK+ Non-Small Cell Lung...

Project Oncology® ·

2026/06/24

Guest: Urs Weber, MD As outcomes improve for patients with ALK+ non-small cell lung cancer, attention is shifting toward therapies designed to push disease control even further. Tune in as Dr. Urs Weber examines promising agents in development and discusses the momentum driving the next phase of ALK-targeted treatment. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

en

00:03:45

Beyond ALK Inhibition: Addressing Unmet Needs in...

Project Oncology® ·

2026/06/24

Guest: Urs Weber, MD Advances in targeted therapies have dramatically improved outcomes for patients with ALK-positive non-small cell lung cancer, but new resistance challenges continue to emerge. In this episode, Dr. Urs Weber discusses how cancers adapt to treatment, why off-target resistance and histologic transformation are becoming increasingly important, and where future research may help close critical gaps in care. Dr. Weber is an Assistant Professor in the Division of Medical

en

198 results

Similar Podcasts

النشرة العلمية

مونت كارلو الدولية / MCD

Ciência

RFI Português

天方烨谈

基因频道

Quilo de Ciencia - Cienciaes.com

Jorge Laborda

The Field Guides

The Field Guides